MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$24,128,117
Unit: Dollar
Positive Cash Flow Breakdown
Acquired in process research and...
Proceeds from the private placem...
Loss on extinguishment of azora ...
Others
Negative Cash Flow Breakdown
Change in fair value of mileston...
Accrued expenses
Issuance costs from the private ...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Net loss
-51,989,608
3,958,616
-5,981,008
-
Equity-based compensation
137,100
-360,264
147,334
360,830
Change in fair value of milestone warrant rights liability
-8,280,000
-
-
-
Financing expense related to milestone warrant rights liability
2,067,000
-
-
-
Loss from operations
-
-
-
-4,187,357
Loss on extinguishment of azora therapeutics convertible promissory notes
-6,054,000
-
-
-
Amortization of intangible assets
-
-282
141
282
Acquired in process research and development
-46,185,000
-
-
-
Inducement expense
-
-
-
0
Change in value of equity method investment
-181,030
270,770
-76,920
-261,820
Prepaid research and development
-
-
-
0
Change in fair value contingent consideration
-
-
0
150,000
Prepaid expenses and other current assets
-95,182
-180,122
243,896
-144,592
Accrued expenses, related party
-
-
-
0
Accounts payable, related party
-
-
0
48,272
Accrued expenses
-2,548,802
237,736
94,613
-137,547
Accounts payable
1,736,640
-387,794
-114,834
420,988
Net cash used in operating activities
-6,362,599
3,555,636
-1,833,373
-3,334,664
Cash receipt from contingent consideration
-
-
0
-150,000
Net cash assumed in the acquisition of azora therapeutics
5,282,000
-
-
-
Net cash provided by investing activities
5,132,000
-
0
150,000
Proceeds from warrant exercise, net of expenses
-
-
47,040
2,221,932
Net proceeds from sale of common stock
849,716
-3,289,545
477,642
3,127,187
Proceeds from the private placement issuance of pre-funded warrants
26,800,000
-
-
-
Issuance costs from the private placement issuance of pre-funded warrants
2,441,000
-
-
-
Net cash provided by financing activities
25,208,716
-5,558,517
524,682
5,349,119
Net increase in cash and cash equivalents
24,128,117
-2,152,881
-1,308,691
2,164,455
Cash and cash equivalents at beginning of period
4,606,289
4,606,289
3,750,525
-
Cash and cash equivalents at end of period
28,712,000
4,584,100
4,606,289
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from the private
placement issuance of...
$26,800,000
Net cash assumed in
the acquisition of...
$5,282,000
Net proceeds from
sale of common stock
$849,716
(-72.83%↓ Y/Y)
Net cash provided by
financing activities
$25,208,716
(371.27%↑ Y/Y)
Net cash provided by
investing activities
$5,132,000
(3321.33%↑ Y/Y)
Canceled cashflow
$2,441,000
Net increase in cash
and cash...
$24,128,117
(1014.74%↑ Y/Y)
Canceled cashflow
$6,362,599
Issuance costs from the
private placement...
$2,441,000
Acquired in process
research and development
-$46,185,000
Loss on
extinguishment of azora...
-$6,054,000
Financing expense related
to milestone...
$2,067,000
Accounts payable
$1,736,640
(312.52%↑ Y/Y)
Change in value of
equity method...
-$181,030
(30.86%↑ Y/Y)
Equity-based compensation
$137,100
(-62.00%↓ Y/Y)
Prepaid expenses and
other current assets
-$95,182
(34.17%↑ Y/Y)
Net cash used in
operating activities
-$6,362,599
(-90.80%↓ Y/Y)
Canceled cashflow
$56,455,952
Net loss
-$51,989,608
Change in fair value of
milestone warrant rights...
-$8,280,000
Accrued expenses
-$2,548,802
(-1753.04%↓ Y/Y)
Buy us a coffee
ADIAL PHARMACEUTICALS, INC. (ADIL)
ADIAL PHARMACEUTICALS, INC. (ADIL)